A n association between diabetes and the risk of heart failure has been seen in observational studies. The mechanism is undefined, and it remains unclear whether dipeptidyl peptidase (DPP)-4 this association is related to concomitant medical problems associated with diabetes (e.g., ischemic heart disease, renal dysfunction, hypertension) or the direct effect of poorly controlled blood glucose.
used with caution in patients with heart failure (1, 2) .
In this issue of JACC Heart Failure, Weir et al. (3) report on their finding that the dipeptidyl peptidase inhibitor sitagliptin is associated with hospitalization for heart failure in patients recently diagnosed with heart failure. The authors carefully performed this analysis in a cohort of patients identified in a large insurance claims database who had type 2 diabetes (taking metformin or a sulfonylurea) and newly diagnosed heart failure. Within this cohort, they identified all cases with the primary outcome of interest and matched them with up to 10 similar controls. They then performed a nested case-control study to determine the odds of a variety of endpoints in patients with diabetes and newly diagnosed heart failure taking sitagliptin versus those not taking sitagliptin.
The authors found no overall association between sitagliptin and the composite endpoints of all-cause death or hospital admission and death or heart failure admission. In addition, they found no association between the individual endpoints of all-cause death or hospital admission. However, they did find a statistically significant association between sitagliptin and heart failure admission that was present even after adjusting for potential confounders (adjusted odds ratio: 1.84; 95% confidence interval [CI]: 1.16 to 2.92; p ¼ 0.01).
The finding that sitagliptin is associated with hospitalization due to heart failure adds to the known associations of other diabetes medications with heart failure. For example, fluid retention may occur in patients treated with thiazolidinedione medications. trial, which was funded by AstraZeneca and Bristol-Myers Squibb. The results of these clinical trials have refocused attention on the relationships among diabetes, the medications used to treat diabetes, and heart failure.
As such, the association described in the current analysis, which is of considerable interest given the Also, the relative effect of sitagliptin on the odds of heart failure admission was moderate, and this association was based on a small number of events. Of the 824 admissions to the hospital for heart failure during follow-up, the patient had been taking sitagliptin over the prior 90 days in only 25 cases. This would be considered very few events in a clinical trial.
Furthermore, the observations were derived from a large insurance claims database in which there is significant potential for misclassification bias. This is of importance for this particular analysis given the impact that a change in only a few events could have on the overall association that was seen.
With these considerations in mind, the present has randomized approximately 14,000 patients with type 2 diabetes to sitagliptin or placebo (9) , and it may help establish whether the class of DPP-4 inhibitors does indeed cause heart failure. Further subgroup and biomarker analyses from recently completed trials may also add insight. In the meantime, diabetic patients at risk for heart failure hospitalization (e.g., those with pre-existing heart failure) who are started on DPP-4 inhibitors, and perhaps diabetes medications in general, should be followed closely as outpatients for symptoms and signs of heart failure.
